Structured intelligence coverage

Structured records are temporarily unavailable. The published profile and its source ledger remain accessible.

Identity checks do not refresh the age of governance evidence. Open a record for its source date and review state.

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
22 current organizations shown on this profile
Board positions
22 supported by public sources, 0 supplied by the profile owner
Committee roles
1Roles supported by the sources cited on this profile
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Thomas J. Falk serves as Independent Lead Director and Chair of the Nominating and Corporate Governance Committee. He is the former Chairman and CEO of Kimberly-Clark Corporation and brings extensive board leadership experience and strategic perspective on global trends and business transformation.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Director

AbbVie (NYSE: ABBV)

Jan 1, 2025 – Present

Independence: Not stated

Source effective: 2025-01-01 · Observed: 2026-05-03T01:47:43.403056+00:00

confirmedView source

Governance

Board appointments, committee responsibilities and disclosed relationships.

Committee appointments across companies · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

AbbVie

2025-01-01 · current

Confirmed by public sourceView source

Lead Independent Director

Lockheed Martin

Current · start date not disclosed

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

AbbVie

Open AbbVie profile →

Director at AbbVie

2025-01-01 → End not stated

current · source reported

Observed: 2026-09-24

AbbVieAbbVieLockheed MartinLockheed MartinThomas J. Falk

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:thomas-j-falk
Record version
public-0

Published evidence records

7 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Lockheed Martin director board source

    sec filing · Source published: Mar 26, 2026 · Retrieved: May 3, 2026

    Supports 3 claims
    • Board independence: Independent director · Claim reviewed: May 3, 2026
    • Board membership: Serves on the board of Lockheed Martin · Claim reviewed: May 3, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 3, 2026
  2. Open source

    sec filing · Source published: Mar 26, 2026 · Retrieved: May 3, 2026

    Supports 1 claim
    • Professional Role: Lead Independent Director at Lockheed Martin · Claim reviewed: May 15, 2026
  3. AbbVie director board source

    sec filing · Source published: Mar 23, 2026 · Retrieved: May 3, 2026

    Supports 4 claims
    • Board independence: Independent director · Claim reviewed: May 3, 2026
    • Board membership: Serves on the board of AbbVie · Claim reviewed: May 3, 2026
    • Board membership: Serves on the board of Lockheed Martin · Claim reviewed: May 3, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 3, 2026
  4. LMT DEF 14A director slate

    sec filing · Source published: Mar 27, 2025 · Retrieved: May 15, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Board role: Board role: Lead Independent Director · Claim reviewed: May 15, 2026
    • Committee assignments: Committee assignments: Nominating/Governance · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 15, 2026
  5. Open source

    sec filing · Source published: Jan 1, 2025 · Retrieved: May 3, 2026

    Supports 1 claim
    • Professional Role: Director at AbbVie · Claim reviewed: May 15, 2026
  6. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of AbbVie · Claim reviewed: May 3, 2026
  7. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Lockheed Martin · Claim reviewed: May 3, 2026

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · Source reportedAI and ML experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Board independence · CorroboratedIndependent directorSupported by 2 public records2 sources
Verification
Corroborated
Confidence
95%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Board membership · CorroboratedServes on the board of AbbVieSupported by 3 public records2 sources
Verification
Corroborated
Confidence
95%
Last reviewed
May 3, 2026
Board membership · CorroboratedServes on the board of Lockheed MartinSupported by 3 public records3 sources
Verification
Corroborated
Confidence
95%
Last reviewed
May 3, 2026
Board role · Source reportedBoard role: Lead Independent Director1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Committee assignments · CorroboratedNo committee assignment disclosed in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
95%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Committee assignments · Source reportedCommittee assignments: Nominating/Governance1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Cybersecurity experience · Source reportedCybersecurity experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Technology background · Source reportedTechnology background: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

View all sources7 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

    Supports: Board membership · Committee assignments · Board independence

  2. https://www.sec.gov/Archives/edgar/data/936468/000093646826000004/lmt-20260326.htm

    Sec Filing · Tier not stated · Reviewed May 3, 2026

    Supports: Lead Independent Director at Lockheed Martin (NYSE: LMT)

  3. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

    Supports: Board membership · Committee assignments · Director since · Board independence

  4. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Cybersecurity experience · Technology background

  5. https://www.sec.gov/Archives/edgar/data/1551152/000110465926033387/abbv-20260508xdef14a.htm

    Sec Filing · Tier not stated · Reviewed May 3, 2026

    Supports: Director at AbbVie (NYSE: ABBV)

  6. https://www.sec.gov/Archives/edgar/data/1551152/000110465926033387/abbv-20260508xdef14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  7. https://www.sec.gov/Archives/edgar/data/936468/000093646826000004/lmt-20260326.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership